Skip to content

Study · Other design · n = 13 · 2015

3 results

Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.

Petri KC, Jacobsen LV, Klein DJ

Clinical pharmacokinetics1 Jun 2015Cited by 26 (Europe PMC)

PMID25603819 (opens in a new tab)PMCIDPMC4449373 (opens in a new tab)DOI10.1007/s40262-014-0229-z (opens in a new tab)PepBankPUB-25603819
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanOther designPharmacokinetics

    In pediatric patients with type 2 diabetes, the model-derived AUC24 slope indicated dose proportionality of liraglutide in the 0.3-1.8 mg dose range.

    In plain wordsIn children and teenagers with type 2 diabetes, liraglutide exposure rose in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    Not applicableDose proportionality of AUC24
    Study

    n = 13

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3-1.8 mgAs given in this study (human).

    Source sentences

    Summary
    Dose proportionality in the dose range of 0.3-1.8 mg was indicated by the model-derived AUC24 slope: 1.05 (95% CI 0.96-1.15).
    1 context sentence
    Summary · context
    A one-compartment pharmacokinetic model previously found to adequately describe the pharmacokinetics of liraglutide in adults with T2D was applied to the evaluation of 13 pediatric subjects (10-17 years of age) with T2D.
  2. 02HumanOther designPharmacokinetics

    In pediatric patients with type 2 diabetes, body weight and gender were relevant covariates for liraglutide exposure, as in adult trials.

    In plain wordsIn children and teenagers with type 2 diabetes, body weight and sex affected how much liraglutide reached the blood, as in adults.

    Peptide
    Liraglutide
    Outcome
    Not applicableCovariates of liraglutide exposure
    Study

    n = 13

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3-1.8 mgAs given in this study (human).

    Source sentences

    Summary
    Consistent with findings from adult trials, body weight and gender were relevant covariates for liraglutide exposure in the pediatric population.
    1 context sentence
    Summary · context
    A one-compartment pharmacokinetic model previously found to adequately describe the pharmacokinetics of liraglutide in adults with T2D was applied to the evaluation of 13 pediatric subjects (10-17 years of age) with T2D.
  3. 03HumanOther designPharmacokinetics

    In pediatric patients with type 2 diabetes, estimates of CL/F and thus liraglutide exposure were similar to those in adult trials.

    In plain wordsIn children and teenagers with type 2 diabetes, liraglutide exposure was similar to that in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changeApparent clearance (CL/F) and exposure versus adults
    Study

    n = 13

    Comparator
    Adults with type 2 diabetes
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3-1.8 mgAs given in this study (human).

    Source sentences

    Summary
    The CL/F estimates, and thus exposure, for the pediatric subjects with T2D were similar to those in the adult trials.
    1 context sentence
    Summary · context
    A one-compartment pharmacokinetic model previously found to adequately describe the pharmacokinetics of liraglutide in adults with T2D was applied to the evaluation of 13 pediatric subjects (10-17 years of age) with T2D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00943501

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Novo Nordisk A/Sn = 21Nov 2009 to Sept 2011

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2017
CompletedPhase 1NCT00993304

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

Novo Nordisk A/Sn = 20Oct 2009 to Dec 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.